Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
ADA 2026
Impact of Once-Weekly Injectable Semaglutide Versus Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP 1)
ADA 2026
ADA 2026
5 - 8 June 2026
Impact of Once-Weekly Injectable Semaglutide Versus Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP 1)
Authors
:
Gema Frühbeck
1
; Maximilian Jara
2
; Naveen Rathor
3
; Jonathan Sudkamp
4
; Lauren Wilson
2
Affiliations
View Details
Hide Details
Download .PDF
Share
Copy link
{{pageUrl}}
Keywords
Obesity
Congress poster
GLP-1 RA
Semaglutide
RWE HEOR